We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.35 | 1.28% | 27.60 | 27.20 | 28.00 | 27.60 | 27.25 | 27.25 | 646,016 | 10:22:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.65 | 185.4M |
From Jul 2019 to Jul 2024
TIDMHVO
RNS Number : 2431X
hVIVO plc
26 April 2019
hVIVO plc
("hVIVO" or the "Company")
2018 Annual Report and Financial Statements and Annual General Meeting 2019
London, UK - 26 April 2019: hVIVO plc (AIM: HVO), announces that the following documents have been sent to shareholders.
Hot Features
Premium
-- Annual Report and Financial Statements for the year ended 31 December 2018
-- Notice of Annual General Meeting ("AGM") 2019
-- Form of Proxy for the AGM
In accordance with AIM Rule 26, these documents are available on Company's website at, http://hvivo.com/investors/financial-reports/.
The AGM is scheduled to be held at 10.00am BST on Thursday 30 May 2019 on 3(rd) Floor, Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX.
For further information please contact:
hVIVO plc Trevor Phillips (Executive Chairman) +44 207 756 1300 Shelley Fraser (Finance Director & Company Secretary) Fleur Wood (EVP, Investor Relations & Communications) Numis Securities Limited +44 207 260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser) James Black / Michael Burke (Corporate Broking) FTI Consulting Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2700 volunteers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACSSELSAMFUSEIL
(END) Dow Jones Newswires
April 26, 2019 04:56 ET (08:56 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
